Peripheral artery disease (PAD) is a disease of great importance to public health, affecting nearly 220 million people worldwide in 2021. It is the third most common clinical manifestation of atherosclerosis after coronary and cerebral localization. Its study and the determination of its public significance are still not sufficiently popular. The high rates of morbidity and mortality among patients with peripheral artery disease raise questions about the need to improve treatment strategies. There is still no established unified, clear, and effective model for assessing the prevalence of the disease in populations, the recommended pharmacotherapy, as well as the frequency and timing of meetings with vascular specialists.
Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711–2.
Birmpili P., Atkins E., Boyle JR. A Best Practice Clinical Care Pathway for Peripheral Arterial Disease J.Vasc.Soc.G.B.Irel. 2022;1(Supp3):S1–S13.
Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022 Mar;31(2):129-137.
Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–30.
FGR Fowkes, D Rudan, I Rudan, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis Lancet, 382 (2013):1329-1340.
Gorter PM, Olijhoek JK, van der Graaf Y, et al. SMART Study Group Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:363–9.
Haas TL, Lloyd PG, Yang HT, Terjung RL. Exercise training and peripheral arterial disease. Compr Physiol. 2012 Oct;2(4):2933-3017.
Mukherjee D, Yadav JS. Update on peripheral vascular diseases: from smoking cessation to stenting. Cleve Clin J Med. 2001;68:723–33.
Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344–53.
Rammos, Christos et al. Peripheral artery disease in Germany (2009–2018): Prevalence, frequency of specialized ambulatory care and use of guideline-recommended therapy – A population-based study The Lancet Regional Health – Europe, Volume 5, 100113.
Schror K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4(Suppl 2):S14–9.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national health and nutrition survey, 1999–2000. Circulation. 2004;110:738–43.
Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3(2):229-34.
Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019 Aug;7(8):1020-1030.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502.
